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with development of the soft tissue morcellator to allow complete 
enucleation.7
To the best of our knowledge, sexual function in men who have 
undergone ThuLEP has not been evaluated in a prospective study 
relying on validated instruments. Therefore, in the current study, we 
assessed the effect of ThuLEP on sexual function of some patients with 
LUTS secondary to BPH and retrograde ejaculation.
PATIENTS AND METHODS
Patients’ selection
We performed a prospective study on changes in sexual function. 
The study was approved by our Local Ethical Committee. A total of 
180 consecutive patients, who had symptomatic BPH and had a surgical 
indication according to EAU Guidelines,3 were enrolled in this study 
from January 2012 to January 2013. Patients who were older than 
80 years old who had previous open or endoscopic management of 
BPH and abdominal surgery, were not included in the study to avoid 
any bias related to postsurgical overactive bladder syndrome.
Treatment and follow‑up
According to the exclusion criteria mentioned below, 110 patients 
were recruited and each of them was treated with ThuLEP with the 
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a common medical condition. 
Transurethral resection of the prostate is currently considered the 
surgical gold standard worldwide to treat BPH, as well as open 
prostatectomy (Millin vs the transvesical approach) for an enlarged 
prostate. Nevertheless these procedures often expose older patients 
to increased perioperative morbidity.1,2
Indications for surgical treatment of BPH are explained in the EAU 
Guidelines and are strictly related to lower urinary tract symptoms (LUTS).3 
Holmium laser enucleation of the prostate (HoLEP), which is a further 
option, is also performed as an accepted alternative to transurethral 
resection of the prostate and open procedures.4 The effects of the latest 
surgical procedures for treating BPH have been poorly studied, and their 
effect on the quality of sexual function, mainly associated with ejaculation, 
is unknown. Previous studies have reported a consistent decrease in the 
International Index of Erectile Function 5 (IIEF-5) score, which measures 
orgasmic function, without any difference among analyzed procedures.5
Thulium laser enucleation of the prostate  (ThuLEP) is a new 
procedure for treating BPH.6 The 2010 nm-wavelength thulium laser 
conducts through saline and enables incision and coagulation of 
prostatic tissue. Similar to HoLEP, ThuLEP has been implemented 
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Treatment of patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) may affect 
the quality of sexual function and ejaculation. The effect of new surgical procedures, which are currently available to treat 
BPH, on erection and ejaculation, has been poorly studied. This study aimed to assess the effect of thulium laser enucleation 
of the prostate (ThuLEP) on sexual function and retrograde ejaculation in patients with LUTS secondary to BPH. We performed 
a prospective study in 110 consecutive patients who had undergone ThuLEP to analyze changes in sexual function and urinary 
symptoms. To evaluate changes in erection and ejaculation, and the effect of urinary symptoms on the quality of life (QoL), five 
validated questionnaires were used: the ICIQ-MLUTSsex, MSHQ-EjD, International Index of Erectile Function 5, International 
Prognostic Scoring System (IPSS) questionnaire, and QoL index of the intraclass correlation coefficients. Patients also underwent 
IPSS and flowmetry to assess the outcome of flow. Patients were evaluated before surgery and 3–6 months after ThuLEP, whereas 
those with previous abdominal surgery were excluded. The patients’ mean age was 67.83 years. Postoperative urinary symptoms 
improved after surgery. No significant differences in erectile function before and after surgery were observed. As compared with 
other techniques described in the literature, the percentage of patients with conserved ejaculation increased by 52.7% after 
ThuLEP. ThuLEP positively affects urinary symptoms and their effect on the QoL of patients as assessed by questionnaire scores. 
While endoscopic management of BPH (e.g. transurethral resection of the prostate) causes retrograde ejaculation in most patients, 
those who undergo ThuLEP have conserved ejaculation and erectile function.
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Cyber TM 150 device (Quanta System, Solbiate Olona, Varese, Italy). 
All of the surgical procedures were performed by three surgeons (LC, 
SC, and GB) who were fully trained in ThuLEP. This surgical technique 
has already been previously described.6 A maximum power of 110 W 
was set for each case. The Piranha Morcellator device (Richard Wolf, 
Knittlingen, Germany) was used at the end of the enucleation step. 
Postoperative Foley catheter irrigation was performed and removed 
the day after surgery. Patients were assessed by a prostate physical 
examination, total serum prostate specific antigen levels, digital 
rectal examination, urine culture, transrectal ultrasound (TRUS) (to 
evaluate prostatic volume), the International Prognostic Scoring 
System  (IPSS), and uroflowmetry. Some of them also underwent 
a urodynamic study to assess whether detrusor hypocontractility 
could explain altered flow. Patients with a prostate specific antigen 
level higher than 4 ng ml−1 underwent TRUS biopsy to exclude cases 
of prostatic carcinoma.
Questionnaires and statistical analysis employed
To assess changes in erection and ejaculation, and the effect of urinary 
symptoms on the quality of life (QoL), five validated questionnaires were 
used: the ICIQ-MLUTSsex, MSHQ-EjD,8 IIEF-5, IPSS questionnaire, 
and QoL Index of the intraclass correlation coefficients. Patients 
were evaluated preoperatively and at 3 and 6 months after ThuLEP. 
Flowmetry was performed during the follow-up period to assess 
changes in flow. Patients were asked not to ride a bicycle or motorbike 
during the 1st month after surgery to decrease the risk of hematuria 
and clot retention.
The collected data were analyzed by an online regression (Student’s 
t-test, Chi-square test, and logistic regression analysis) tool at 
www.xuru.org using linear least squares fittings. For all statistical 
comparisons, significance was considered at P < 0.05.
RESULTS
Table  1 shows the patients’ characteristics. The patients’ mean 
age was 67.83  years  (standard deviation  [s.d.]: 7.74; range: 
52.28–85.13  years). The mean prostate volume was 75.46  ml 
(s.d.: 43.75; range: 21.77–235.12 ml). Sixty-nine (62.7%) patients had 
been previously treated with alpha blockers, while six of them (8.7%) 
received a combination of finasteride and alpha blockers. Not all of the 
patients (16/110, 14.5%) reported a stable heterosexual relationship of 
at least 6 months duration. Thirty-one (28.2%) patients had undergone 
TRUS biopsy before ThuLEP.
Table  2 shows the changes in scores of the questionnaires 
used. Table 3 shows flowmetry results. A  significant and sustained 
improvement in the scores of questionnaires for evaluating urinary 
symptoms was observed. There was no significant difference in 
patients’ erectile function before and after surgery. Analysis of 
the postoperative MSHQ-EjD showed 58  (52.7%) patients with 
consistent ejaculation function  (EF) after ThuLEP. This rate was 
78.4%  (58/74) when we excluded patients with previous ED, no 
possibility of having sexual intercourse, and those with previous 
ejaculatory dysfunction not related to alpha blockers. Seven of the 
58  patients  (12.1%) reported painful ejaculation. Analysis of the 
postoperative ICIQ-MLUTSsex questionnaire showed no significant 
change in erectile function after ThuLEP. A similar result was obtained 
for the IIEF-5 Questionnaire  (Table  4). Interestingly, patients who 
maintained their antegrade ejaculation were found to be more sexually 
satisfied than the other patients.
A total of 51.7% (30/58) of patients expertise blood in seminal 
liquid after the surgical procedure. All of these patients who had 
undergone TRUS biopsy, also experienced it. Eight  (7.3%, 8/110) 
patients were re-admitted because of clot retention. Adverse events, 
as well as operative and postoperative findings are shown in Table 5. 
Two patients had to be re-operated during hospitalization because of 
gross hematuria after accidental catheter removal. No ureteral strictures 
were observed during follow-up.
DISCUSSION
Benign prostatic hyperplasia is a common condition in middle-aged and 
older men. Many surgical treatments have been offered as alternative 
to current BPH gold standards.3 Most of these treatments are not 
as durable or effective as TURP and open prostatectomies for BPH, 
and these surgical techniques still have a consistent rate of morbidity. 
Even in skilled hands, bleeding and TUR syndrome remain the most 
Table 1: Patients characteristics
Patient characteristics Mean±s.d. (range)
Age (year) 67.83±7.74 (52.28–85.13)
Weight (kg) 76.92±10.98 (52.50–110.00)
Height (m) 1.72±0.07 (1.60–1.91)
BMI 25.82±3.57 (18.30–35.50)
Prostatic volume (cm3) 75.46±43.75 (21.77–235.12)
Aden volume (cm3) 42.93±31.57 (7.30–167.54)
PSA (ng ml−1) 3.52±3.21 (0.42–14.73)
Dysuria (year) 5.51±4.13 (1.50–10.25)
Alpha-blocker, n (%) 69 (62.7)
BMI: body mass index; PSA: prostate specific antigen; s.d.: standard deviation
Table 2: Changes in scores on the questionnaires employed
Outcomes Data preoperation At 3 months At 6 months
IPSS, mean±s.d. 18.12±6.73 6.85±5.36 4.38±4.99
QoL, mean±s.d. 4.23±1.44 2.16±1.77 1.49±1.60
IIEF 5, mean±s.d. 16.84±4.45 16.47±3.18 18.10±3.81
Erection conserved 
ICIQ-MLUTSsex, n (%)
87 (79.1) 87 (100) 87 (100)
Ejaculation conserved 
MSHQ-EjD, n (%)
74 (67.2) 58 (52.7) 58 (52.7)
s.d.: standard deviation; IPSS: International Prognostic Scoring System; QoL: quality of 
life; IIEF: International Index of Erectile Function
Table 3: Flowmetry improvement
Uroflowmetry 
months
Preoperation At 3 months At 6 months
Qmax (ml s
−1) 9.60±6.11 20.20±10.23 22.14±9.85
Qavg (ml s
−1) 4.56±1.77 11.08±6.69 12.30±6.01
Volume (cm3) 198±85 259±127 241±131
Data are presented as mean±s.d.
Table 4: Postoperative outcomes on erection and ejaculation 
(MSHQ‑EjD and ICIQ‑MLUTSsex)
ICIQ‑MLUTSsex 
conserved MSHQ‑EjD
Erection 
conserved, n (%)
Ejaculation, 
n (%)
Yes 87 (79.1) 58 (52.8)
No 0 (0) 16 (14.5)
Don’t know 3 (2.7) 16 (14.5)
Previous ED 20 (18.2) 20 (18.2)
Total 110 (100) 110 (100)
ED: erectile dysfunction
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dangerous complications for patients undergoing TURP.9,10 Bleeding, 
length of hospitalization, and postoperative detrusor contractions, 
besides common complications following any open surgical approach, 
are quite frequent in any open prostatectomy performed for large BPH.1,2
Laser-based techniques for BPH have increased in recent years. 
Their characteristics determine their versatility in BPH and endoscopic 
treatments for stones. HoLEP is equivalent to TURP and open 
prostatectomies with respect to clinical outcomes and QoL. However, 
HoLEP is superior with regard to perioperative morbidity with reduced 
bladder irrigation, catheter time and hospital stay, even though an 
equivalent volume of prostatic tissue is resected or enucleated.11
Thulium laser enucleation of the prostate is currently used to 
treat BPH.6,12,13 Gross et al.14 showed that, similar to HoLEP, thullium 
vapo-enucleation of the prostate  (ThuVEP), which has a different 
surgical technique, has an equivalent clinical outcome on LUTS 
compared with gold standard techniques. ThuVEP also minimizes 
the transfusion rate, the length of hospitalization, and postoperative 
complications.
Some evidence supports the theory that BPH combined with 
sexual and ejaculatory dysfunction are simply coexisting, and 
this is mainly related to metabolic and hormonal changes, usually 
affecting men.5 The multinational survey of the aging male, 
Table 5: Operative and postoperative findings and adverse events
Findings Rate
Stop bladder irrigation (h, mean±s.d.) 20.21±12.82
Catheter removal (h, mean±s.d.) 33.00±13.93
Acute urinary retention, n (%) 8 (7.3)
Discharge (day, mean±s.d.) 2.44±1.45
Hemoglobin decrease (g dl−1) Δ–1.05
Blood transfusion (n) 2
Operative time (min, mean ±s.d.) 82.00±43.77
Incidental tumors adenocarcinoma (n) 4
Presence of TCC of the bladder (n) 3
Coagulation of bleeders in the prostatic fossa (n) 2
SD: standard deviation; TCC: transitional cell carcinoma
Table 7: Sexual outcome compared to preoperative prostatic volume
Prostatic volume (ml) Patient (n) Erection conserved Ejaculation conserved
<40 39 32 20
Between 40 and 100 39 28 20
>100 32 27 18
Total 87 58
P >0.5 >0.5
Table 6: Outcome of male sexual function in different laser prostate surgical techniques
Author Laser technique Laser type n Assessment tool Control Outcome (EF and retrograde ejaculation) %
Montorsi et al. 
200420
Enucleation (HoLEP) Ho:YAG 52 IIEF-15 TURP EF did not show a change from 
baseline
-
Briganti et al. 
200619
Enucleation (HoLEP) Ho:YAG 32 IIEF-15 TURP Reduced orgasmic function 
domain significantly with 
marginal EF improvement
78.3
Wilson et al. 
200611
Enucleation (HoLEP) Ho:YAG 31 Nonvalidated 
questionnaire
TURP Potency; 3.9 improved, 3.9 
deteriorated 6.5 new onset ED
75
Meng et al. 
200721
Enucleation (HoLEP) Ho:YAG 108 DanPSS sex None Do not affect the sexual functions 
significantly but improve ability 
to achieve early morning erection
70
Jeong et al. 
201222
Enucleation (HoLEP) Ho:YAG 38 IIEF None EF did not show a change from 
baseline
52
Bach et al. 
201123
ThuVEP Thulium:YAG 90 IIEF-5 None Marginal nonsignificant EF 
improvement
-
Yee et al. 
201224
Vaporesection 
(ThuVaRP)
Thulium:YAG 113 - None 20% experienced worsening 
erectile function
56
Elmansy et al. 
201025
Ablation (PVP) 
(HoLAP)
Green light - 
KTP - Ho:YAG
30 33 IIEF-15 2 types of 
laser
EF did not show a change from 
baseline
43.3
36.3
Horasanli et al. 
200826
Ablation (PVP) Green light - KTP 39 IIEF-5 TURP EF did not show a change from 
baseline
49.9
Kavoussi and 
Hermans 200827
Ablation (PVP) Green light - KTP 105 SHIM None EF did not show a change from 
baseline
-
Spaliviero et al. 
201028
Ablation (PVP) Green light - LBO 72 SHIM None No detrimental effect on EF 30
Bouchier-Hayes 
et al. 201029
Ablation (PVP) Green light - KTP 60 BSFQ TURP EF did not show a change from 
baseline
-
Bruyère et al. 
201030
Ablation (PVP) Green light - 
KTP - LBO
149 63
86
IIEF-5 None Significant decrease in EF in 
patients with basal IIEF-5≥19
70
Kumar et al. 
201231
Ablation (PVP) Green light - KTP 150 IIEF-5 None Significant decrease in EF in 
patients with basal IIEF-5≥19 
-
Hossack and Woo 
201232
Ablation (PVP) Green light - LBO 328 IIEF-5 None Significant decrease in EF 65
Elshal et al. 
201233
Enucleation (HoLEP)
Ablation (HoLAP)
Ablation (PVP)
Ho:YAG
Green light
191 IIEF-15 Three types 
of laser
Laser prostate surgery using more 
size-related laser energy might 
have possible negative influence 
on sexual function
77.3 (HoLEP)
31 (HoLAP)
33.2 (PVP)
PVP: photoselective vaporization of the prostate; HoLEP: holmium laser enucleation of the prostate; HoLAP: holmium laser ablation of the prostate; ThuVEP: thullium vapo-enucleation 
of the prostate; ThuVaRP: thulium laser vaporesection of the prostate; IIEF: International Index of Erectile Function; Ho:YAG: holmium:yttrium aluminum garnet; LBO: lithium triborate 
laser; KTP: potassium titanyl phosphate; BSFQ: Brief Sexual Function Questionnaire; SHIM: sexual health inventory for men; TURP: transurethral resection of the prostate
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a large-scale, multinational survey on approximately 14,000 men 
aged 50–80 years, reported that although 90% of men had LUTS, 
83% of them still had sexual activity.15 This survey also highlighted 
that erectile and EF play an important role in the QoL, even in aged 
men with symptomatic BPH.
Some studies have provided controversial evidence regarding 
postoperative erectile dysfunction  (ED) after TURP and open 
prostatectomies for BPH.16,17 Wasson et  al.18 investigated ED after 
TURP in an untreated group and did not find any increase in the 
rate of ED in the TURP group. Induced neuropraxia by different 
forms of energy has been indicated as a possible reason of a transient 
postoperative ED. Conversely, evidence has indicated a strict 
correlation between surgical management of BPH and retrograde 
ejaculation. To the best of our knowledge, our study is the first to 
focus on sexual and EF after ThuLEP.
Briganti et  al.19 achieved an equivalent outcome with regard 
to ED and EF between TURP and HoLEP. This suggests that these 
two surgical approaches are similarly associated with a high risk of 
postoperative ejaculatory dysfunction, mainly owing to retrograde 
ejaculation. Our series, using different questionnaires preoperatively 
and postoperatively, showed an overall conservation rate of antegrade 
ejaculation of 52.7%. If only those patients with possibilities of sexual 
intercourse were included, this rate was 78.3%. However, the rate of ED 
after ThuLEP was only 2.7% (Table 4). Table 6 shows the outcomes of 
male sexual function in different laser prostate surgical techniques; the 
final results can be easily compared with those of the current study.11,20–33
Several previous studies, mainly on alpha blockers, have shown how 
antegrade ejaculation can positively affect sexual satisfaction. There were 
also no significant differences in EF among three different groups with 
regard to prostatic volume (<40 ml, ≥40 ml and <100 ml, >100 ml). It 
is not the prostatic volume that may affect or not antegrade ejaculation 
after ThuLEP (Table 7). The reason for such a good result could be 
related to the surgical technique of laser enucleation of the prostate.6 
A less deep incision typical of a thulium laser device (0.1–0.2 mm) can 
also determine the absence of transient ED because it does not involve 
neurovascular bundles of the capsule in the so-called neuropraxia 
phenomenon.34 On the same hand similar aspects have been underlined 
by a recent study by Xia.35 Further, from an anatomical and prospective 
view, further studies are required to better understand how EF can be 
better preserved. Also a comparison to TURP in a prospective study 
would have possibly shown the good results of ThuLEP regarding EF.
In our study, the good results on the postoperative IPSS and 
flowmetry showed that ThuLEP allowed radical prostatic adenoma 
enucleation. Preserved antegrade ejaculation was not correlated to 
partial enucleation of prostatic adenoma, as normally occurs during 
alpha blocker therapy when retrograde ejaculation appears and 
disappears once therapy is stopped.
A reduced learning curve is another important advantage of the 
proposed new surgical technique.6 This can be achieved with the help of 
a PC-based dry simulator and 15–20 tutorated cases. The dry simulator 
is made by Quanta System.
In the current study, clot retention was the main complication 
owing to anticoagulants taken by patients because of cardiovascular 
issues. Blood in seminal fluid is a surgical-related side effect, mainly 
found in patients with a previous TRUS biopsy.
CONCLUSIONS
Thulium laser enucleation of the prostate is an efficient technique, 
which is performed with a safe energy source. ThuLEP represents 
a simple new shift in the endoscopic management of BPH and can 
be used to treat prostates of any size. This technique improves the 
scores of questionnaires that are used to assess urinary symptoms and 
their effect on the QoL in patients. Antegrade ejaculation is mainly 
conserved in patients who undergo ThuLEP, with good effects on 
erectile function. Further, from a mainly anatomical and prospective 
view, further studies are required to better understand how EF can be 
better preserved with ThuLEP.
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